

The Malaria Elimination Working Group

US Naval Medical Research Unit No. 6 (NAMRU-6)

Lima, Iquitos and Puerto Maldonado, Perú



Andres G. (Willy) Lescano, PhD, MHS, MHS
Head, Department of Parasitology
Director, Public Health Training



Disclaimer

The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.

Copyright statement


I am an employee of the U.S. Government. This work was prepared as part of my official duties. Title 17 U.S.C. § 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. § 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.



NAMRU-6 is one of the Infectious Diseases Research Laboratories of the US Military



Headquarters
NMRC / WRAIR
Silver Spring, MD



AFRIMS
Thailand
1959



NMRC-Asia
Singapore
(Cambodia)
1945



NAMRU-6
Perú
1983



NAMRU-3
Egypt (Ghana)
1946



USAMRU-K
Kenya
1969



Infectious Disease Products Developed by Department of Defense Scientists

Research Effort		Advanced Development	Fielded Products
Antiparasitic Drugs	Malaria (CDD)	Intravenous Artesunate (CPD) Tafenoquine	Atovaquone/Proguanil (Malarone®, 2000) Doxycycline (Vibramycin®, 1992) Halofantrine (Halfan®, 1992) Mefloquine (Lariam®, 1989) Sulfadoxine-Pyrimethamine (1983) Chloroquine-Primaquine Tablets (1969) Primaquine (1952) Chloroquine (1949)
	Leishmaniasis	Topical Paromomycin drug (CPD)	
Vaccines	Malaria (CDD) Diarrhea (CDD) Dengue Hemorrhagic fevers Scrub Typhus HIV Global (CDD)	Dengue Tetravalent (CDD) HIV Regional (CDD)	Adenovirus 4 & 7 (1980) – (2011) Japanese Encephalitis - cell based (2009) Hepatitis A (1995) Japanese Encephalitis (1992) Oral Live Typhoid Ty21A (1989) Hepatitis B (1981) Meningococcus (A, C, Y, W-135) (1981)
			
Diagnostics	Laboratory-based assays Point-of-need devices (CDD)	Leishmania Rapid Diagnostic Device Dengue Rapid Diagnostic Device	SMART Leish PCR Diagnostic Test (2011) Scrub Typhus JBAIDS (2010) Malaria Rapid Diagnostic Test (2007) Scrub Typhus Diagnostic Kit (1998)
			
Vector Control & Radioprotecta	Repellents/Insect control Insect identification Vector Diagnostics (CDD)	Combined Camouflage Face Paint Bednet Alternate Repellent System	Arthropod Vector Rapid Detection Device for Dengue (2012) Rift Valley Fever virus Vector Detection Assay (2011) West Nile Virus Diagnostic Kit (2001) Ethylol® (1995) DEET-based Insect Repellent (1946)
			



Staff, Facilities & Research

■ People

- 20 U.S. staff: 16 military
- 300 Peruvian scientists/staff

■ Facilities

- Lima (BSL-3)
 - 41,000 sq ft of laboratory space
 - AAALAC certified lab animal facility
- Iquitos (BSL-2)
 - 5,000 sq ft of laboratory space
 - *Anopheles darlingi* insectary
- Puerto Maldonado (BSL-1)
 - 2,000 sq ft of laboratory space

■ Research

- **Departments:** Bacteriology, Entomology, Parasitology and Virology/Emerging Infections
- **Priorities:** Research, surveillance, product development, outbreak response, capacity building, collaboration



NAMRU-6
Puerto Maldonado




Study Sites



- 147 observational studies in 11 countries, 29 additional animal studies
- Scientific Review Board, Ethics Review Board and Institutional Animal Care and Use Committee (IACUC) since 1995



P. falciparum collaborative clinical trials with INS/USAID



Malaria Journal

Research [Open Access](#)

Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria
Julie Gittman^{1,2}, Michael Green³, Solomon Duran⁴, Ofelia Villalba Rojas⁵, Ralva Ganguly¹, Wilmer Margallo Quezada⁶, Gregory C. Liu¹, Laurence Shikler⁷, Trenton K. Ruebush II⁸ and David J. Bacon⁹

Short Report: Surveillance for Adverse Drug Reaction to Combination Antimalarial Therapy with Sulfadoxine-Pyrimethamine plus Artesunate in Peru
Isabel Caceres, Solomon Duran, Wilmer Margallo, César Cabezas, Anabelle Luchini, Francisco Chantorno, Walter Yegor, Trenton K. Ruebush II, Gregory Liu, and David J. Bacon¹

UNUSUAL PATTERN OF PLASMODIUM FALCIPARUM DRUG RESISTANCE IN THE NORTHWESTERN PERUVIAN AMAZON REGION
WILMER MARGALLO, LAURA VILLOREUIL, FLORE BERNHARDT, ANA MARIA PALACIOS, FRANCISCO CHANTORNO, CÉSAR CABEZAS, ANABELLE LUCHINI, FRANCISCO CHANTORNO, DAVID J. BACON, and TRENTON K. RUEBUSH II¹

EFFICACY AND TOLERABILITY OF ARTESUNATE PLUS SULFADOXINE-PYRIMETHAMINE AND SULFADOXINE-PYRIMETHAMINE ALONE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN PERU
WILMER MARGALLO, LAURA VILLOREUIL, FLORE BERNHARDT, ANA MARIA PALACIOS, FRANCISCO CHANTORNO, CÉSAR CABEZAS, ANABELLE LUCHINI, FRANCISCO CHANTORNO, DAVID J. BACON, and TRENTON K. RUEBUSH II¹

JOURNAL OF PUBLIC HEALTH POLICY - VOL. 25, NO. 3/4
Modifying National Malaria Treatment Policies in Peru
TRENTON K. RUEBUSH II, DANIEL NEYRA, and CÉSAR CABEZAS

Efficacy of sulfadoxine-pyrimethamine and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon basin of Peru
Alan J. Magill¹, Jorge Zegarra², Coralith Garcia³, Wilmer Margallo⁴ and Trenton K. Ruebush II⁵

CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN PERU
TRENTON K. RUEBUSH II, JORGE ZEGARRA, JAVIER LAROS, SILVANA ANDRÉS, MICHAEL GREEN, ISABEL CACERES, ANABELLE LUCHINI, FRANCISCO CHANTORNO, DAVID J. BACON, and TRENTON K. RUEBUSH II¹

Evaluation of a simple operational approach for monitoring resistance to antimalarial drugs in Peru
Trenton K. Ruebush II¹, Antonio Lavea², Victor Gonzalez³, Daniel Neyra⁴ and Wilmer Margallo⁵

Practical aspects of in vivo antimalarial drug efficacy testing in the Americas
TRENTON K. RUEBUSH II, WILMER MARGALLO, JORGE ZEGARRA, DANIEL NEYRA, ROBERTO VELAZQUEZ, JEAN CARLOS SILVA, FRANCISCO CHANTORNO, and FRANCISCO CHANTORNO

EFFICACY OF MEFLOQUINE AND A MEFLOQUINE-ARTESUNATE COMBINATION THERAPY FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN THE AMAZON BASIN OF PERU
WILMER MARGALLO, ANABELLE LUCHINI, CÉSAR CABEZAS, FRANCISCO CHANTORNO, DAVID J. BACON, and TRENTON K. RUEBUSH II¹

EFFICACY OF CHLOROQUINE, SULFADOXINE-PYRIMETHAMINE, AND MEFLOQUINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA ON THE NORTH COAST OF PERU
WILMER MARGALLO, WALTER MARGALLO, LAURA VILLOREUIL, FRANCISCO CHANTORNO, ANABELLE LUCHINI, FRANCISCO CHANTORNO, DAVID J. BACON, and TRENTON K. RUEBUSH II¹

The Malaria Elimination Working Group (MEWoG)

Promoting innovation to accelerate the path towards malaria elimination at the local level

Antonio M. Quispe, MD, MSc,
JHSPH, PhD student
NAMRU-6, Adjunct Scientist




Alan Magill, BMGF Malaria Director

Keynote Speech at ASTMH Peru 2013: An analytic framework to eradicate malaria: accelerating to zero

“Any goal short of eradicating malaria is accepting malaria; it’s making peace with malaria; it’s rich countries saying: ‘We don’t need to eradicate malaria around the world as long as we’ve eliminated malaria in our own countries.’ That’s just unacceptable”
Melinda Gates, 2007

The world has three potential future trajectories for malaria...



Accelerate to Zero

We can accelerate the trajectory to malaria eradication by targeting the human reservoir of infection in asymptomatic persons combined with geographically and temporally targeted transmission prevention and strengthened surveillance and response



How things started



- **Antonio M. Quispe, BMGF Intern Jun-Aug '13**
- **Global Health Conference Grant OPP1099774: “Accelerating to zero: Strategies to Eliminate Malaria in the Amazon”. Universidad Peruana Cayetano Heredia and NAMRU-6**
- **Consortium initially formed**
- **Partnership then expanded to include a multi-institution collaboration**

Who are we?

- *A multi-organizational, multidisciplinary group of malaria researchers and public health practitioners*
- *convened to support the agenda of malaria elimination in the Amazon region*
- *with a particular focus in the Peruvian Amazon Basin*



Our leadership

Our Board

PI's

- Alejandro Llanos
- Andres Lescano
- Antonio Quispe
- Eduardo Gotuzzo
- Joseph Vinetz
- Margaret Kosek

MoH

- Carlos Lluén
- César Cabezas
- Edward Pozo
- Fernando Orihuela
- Fernando Quintana
- Helena Oigusuku
- Jorge Ascencio
- Jorge Escobedo
- Jose Carlos Del Carmen
- Luis Flores
- Luis Miguel León
- Luis Saavedra
- Martín Clendenes
- Martín Yagui
- Pedro Valencia
- Rommel Gonzalez

Regional

- César Ramal
- Cristiam Carey
- Martín Casapía
- Moisés Sihuincha
- Sonia Torres
- Carmen Montalván
- Carlos Álvarez
- Graciela Meza
- Francisco Gallo

National

- Adam Amstrong
- Amy Morrison
- Ángel Rosas
- Christian Baldeviano
- Dionicia Gamboa
- Gissella Vásquez
- Karen Campos
- Maribel Paredes
- Marta Moreno
- Raúl Chuquiyaui
- Vince Gerbasi

International

- Alan Magill
- Brian Grimberg
- David Kaslow
- David Smith
- Fernando Llanos
- Guillermo González
- Jaime Chang
- Max Grogil
- Steven Kern
- Sócrates Herrera
- Steve Harvey




Collaboration is our major strength

Our mission

- **To promote innovative solutions**
- **to address the scientific, technical, operational, financial and programmatic issues**
- **that local authorities need to address**
- **when pursuing or embarking on malaria elimination initiatives**

Our agenda

- Support the implementation of novel strategies to target the malaria reservoir and accelerate the path towards malaria elimination
 - Support the introduction of novel molecular field deployable diagnostics
 - Strengthen local surveillance systems with novel geospatial mapping techniques and targeted transmission prevention measures
- Intensify the collaboration between national and international organizations to support local malaria elimination initiatives
 - Promote forums and policy environments that facilitate the continual experimentation and learning for new tools and strategies for malaria elimination



Iquitos Conference, February 16-17, 2013

- All malaria research groups, international partners and sponsors together with public health authorities
- Presentation of relevant research findings, ongoing and future projects
- Feasibility, outcomes, methods and research agenda
- Critical gaps identified:
 - Targeting the *P. vivax* asymptomatic reservoir
 - Sensitive and deployable tests in resource-limited settings
 - Political commitment and support for continuity
- Commitment to work together in the goal of elimination

Attendants

Ministry of Health: Loreto authorities, hospitals and laboratories. National Institutes of Health, Epidemiology, Vector Borne Diseases Control Strategy, Regional authorities

Research groups: Universidad Peruana Cayetano Heredia, University of California @ San Diego, NAMRU-6, Asociacion Benefica PRISMA, Johns Hopkins & New York Universities

Partners: USAID, PAHO, Walter Reed Army Institute of Research, Latin America and Amazonia International Malaria Centers of Excellence (ICEMR)

Sponsors: Bill and Melinda Gates Foundation, PATH




Next steps


- **Consolidation of grey literature and non-published data into peer-reviewed papers in the international literature**
- **Analysis of existing information to identify potential pilot sites**
- **Preparation of final report of the meeting to consolidate support from the Peruvian Ministry of Health**
- **Active search for funding for elimination projects**
- **Invitation to AMI Steering Committee members to be part of the MEWG Consulting Committee**

Human Malaria Reservoir Loreto - 2007


Histogram of Incidence Rates: 2007



Malaria Incidence Rates by Health Center Loreto, Peru. 2007.




Malaria Incidence Rates by Health Center Loreto, Peru. 2007.




Human Malaria Reservoir Loreto - 2008


Histogram of Incidence Rates: 2008



Malaria Incidence Rates by Health Center Loreto, Peru. 2008.






Malaria Incidence Rates by Health Center Loreto, Peru. 2008.




Human Malaria Reservoir Loreto - 2009

Histogram of Incidence Rates: 2009



Every person
deserves the
chance to live
a healthy,
productive life.
(BMGF Vision)





***Thank you
for your
attention***



**willy.lescano@med.navy.mil
wlescano@hotmail.com**